Meloxicam SBEβCD Inclusion Complex for Rapid Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and delayed pain relief, which can be improved by forming an inclusion complex with cyclodextrins like sulfobutyl ether β-cyclodextrin (SBEβCD) and administering it with a bicarbonate, such as sodium bicarbonate, to enhance solubility and absorption.
Innovation Solution
The combination of meloxicam with SBEβCD and a bicarbonate, like sodium bicarbonate, forms an inclusion complex that increases the bioavailability and rapid absorption of meloxicam, allowing for its effective use in treating pain conditions, including migraines, by forming an inclusion complex that enhances solubility and absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is used as a conventional NSAID, then it provides anti-inflammatory and analgesic activities, but it has poor aqueous solubility which reduces bioavailability and slows onset of pain relief
Solution Approach 1:
The patent uses cyclodextrins as intermediary carriers that form inclusion complexes with meloxicam. The cyclodextrin cavity encapsulates the hydrophobic meloxicam molecule, while the hydrophilic outer surface of cyclodextrin interacts with aqueous environment, thereby improving solubility and bioavailability without altering the active drug molecule itself.
Solution Approach 2:
The patent modifies the physical-chemical parameters of meloxicam by forming inclusion complexes with cyclodextrins. This changes the solubility parameter from poor to improved, and accelerates the dissolution rate, leading to faster onset of action while maintaining the same pharmacological activity.
2Reliability
If the dose of meloxicam is increased to achieve adequate pain relief, then pain relief efficacy improves, but gastrointestinal side effects increase
Solution Approach 1:
Cyclodextrins serve as a protective intermediary that delivers meloxicam to the site of action while reducing direct contact with gastrointestinal mucosa. The inclusion complex modifies the drug's interaction with gastric tissues, maintaining efficacy at lower doses while reducing local irritant effects.
Solution Approach 2:
By improving solubility through cyclodextrin complexation, the patent enables achievement of therapeutic plasma concentrations with lower administered doses, thereby reducing the dose-dependent gastrointestinal side effects while maintaining pain relief efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination significantly increases the bioavailability and rapid absorption of meloxicam, providing rapid and sustained pain relief, reducing the need for rescue medication and improving treatment outcomes in patients with a history of inadequate responses to prior treatments.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
administering it with a bicarbonate, such as sodium bicarbonate, to enhance solubility and absorption
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.